Cargando…
Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048618/ https://www.ncbi.nlm.nih.gov/pubmed/30034548 http://dx.doi.org/10.1177/1758835918782356 |
| _version_ | 1783340130052866048 |
|---|---|
| author | Harbeck, Nadia |
| author_facet | Harbeck, Nadia |
| author_sort | Harbeck, Nadia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6048618 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60486182018-07-20 Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? Harbeck, Nadia Ther Adv Med Oncol Editorial SAGE Publications 2018-07-11 /pmc/articles/PMC6048618/ /pubmed/30034548 http://dx.doi.org/10.1177/1758835918782356 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Editorial Harbeck, Nadia Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? |
| title | Neoadjuvant treatment of HER2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| title_full | Neoadjuvant treatment of HER2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| title_fullStr | Neoadjuvant treatment of HER2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| title_full_unstemmed | Neoadjuvant treatment of HER2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| title_short | Neoadjuvant treatment of HER2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| title_sort | neoadjuvant treatment of her2-positive breast cancer: should therapy
differ based on hormone receptor status? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048618/ https://www.ncbi.nlm.nih.gov/pubmed/30034548 http://dx.doi.org/10.1177/1758835918782356 |
| work_keys_str_mv | AT harbecknadia neoadjuvanttreatmentofher2positivebreastcancershouldtherapydifferbasedonhormonereceptorstatus |